z-logo
open-access-imgOpen Access
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Author(s) -
Scott D. Solomon,
David Adams,
Arnt V. Kristen,
Martha Grogan,
Alejandra GonzálezDuarte,
Mathew S. Maurer,
Giampaolo Merlini,
Thibaud Damy,
Michel Slama,
Thomas H. Brannagan,
Angela Dispenzieri,
John L. Berk,
Amil M. Shah,
Pushkal Garg,
Akshay Vaishnaw,
Verena Karsten,
Jihong Chen,
Jared Gollob,
Joshua R. Vest,
Ole B. Suhr
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.035831
Subject(s) - medicine , cardiac amyloidosis , cardiology , placebo , amyloidosis , population , cardiomyopathy , interventricular septum , heart failure , ventricle , pathology , alternative medicine , environmental health
Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom